key: cord-0825960-2l2q4dum
authors: Abela, I. A.; Pasin, C.; Schwarzmueller, M.; Epp, S.; Sickmann, M.; Schanz, M. M.; Rusert, P.; Weber, J.; Schmutz, S.; Audige, A.; Maliqi, L.; Hunziker, A.; Hesselman, M. C.; Niklaus, C. R.; Gottschalk, J.; Schindler, E.; Wepf, A.; Karrer, U.; Wolfensberger, A.; Rampini, S. K.; Meyer Sauteur, P. M.; Berger, C.; Huber, M.; Boeni, J.; Braun, D. L.; Marconato, M.; Manz, M. G.; Frey, B. M.; Guenthard, H. F.; Kouyos, R. D.; Trkola, A.
title: Multifactorial SARS-CoV-2 seroprofiling dissects interdependencies with human coronaviruses and predicts neutralization activity
date: 2021-04-21
journal: nan
DOI: 10.1101/2021.04.21.21255410
sha: 127569b1e0f3e36649e926dcf249cf89ffa24dcd
doc_id: 825960
cord_uid: 2l2q4dum

Definition of SARS-CoV-2 antibody responses is essential to verify protective immunity following infection and vaccination. Here, we devised a versatile serological test, named ABCORA, that is based on a multifactorial analysis of SARS-CoV-2 and circulating human coronavirus (HCoV) antibody responses. Utilizing empirical tailored cut-offs and computational approaches based on training and validation cohorts comprising pre-pandemic (N=825) and SARS-CoV-2 infected plasma donors (N=389), we defined several analysis strategies that allow a highly accurate definition of SARS-CoV-2 seroconversion and prediction of neutralization activity. Intriguingly, HCoV reactivity was significantly higher in SARS-CoV-2 negative donors. Amongst SARS-CoV-2 infected individuals, elevated SARS-CoV-2 responses were linked to higher HCoV activity suggesting that pre-existing HCoV immunity may confer protection against SARS-CoV-2 acquisition and promote development of SARS-CoV-2 specific antibody responses. Deciphering interdependencies between SARS-CoV-2 and HCoV immunity should be enforced as understanding their impact on infection may allow soliciting cross-protective activities for broader coronavirus prevention.

Monitoring the antibody response to SARS-CoV-2 is critical to define correlates of vaccine protection, 46 differences in susceptibility to infection and in disease severity. The picture of the antibody landscape 47 to SARS-CoV-2 that has thus far evolved is complex. The antibody response to SARS-CoV-2 is rapid, and 48 triggers strong IgM, IgA and IgG responses 1,2 . Both binding and neutralizing responses increase with 49 disease severity and show in part dependence on demographic parameters such as age and gender 3-50 5 . It remains, however, unclear which factors are independent drivers of antibody responses, reflect 51 severe disease courses or are confounded by other factors including infection length and co-52 morbidities. Waning IgG binding and neutralizing antibody titers have been described in some but not 53 all convalescent cohorts and may be particularly pronounced in individuals with asymptomatic or mild 54 infection [6] [7] [8] [9] . IgG responses to spike (S) glycoprotein may persist longer than to nucleocapsid protein 55 (N) 7,10,11 and can in part undergo affinity maturation post virus clearance 5 . Current serological analyses 56 predominantly focus on measuring reactivity to N, the spike glycoprotein S1 subunit and the ACE2 57 receptor-binding domain (RBD) in S1 2,5,12-16 . Antibodies to RBD and the receptor-binding motif within 58 the RBD constitute the main group of neutralizing antibodies, followed by S1 trimer specific, spike N-59 terminal domain, and spike S2 neutralizing antibodies [16] [17] [18] [19] [20] [21] [22] . S1 and RBD binding correlate with 60 neutralizing activity in both natural and vaccine-induced immune responses providing means to 61 estimate the potential for neutralization where neutralization capacity cannot be assessed directly 6,8 . 62 Considering the complex antibody response patterns, possibilities to capture the dynamics of the 63 SARS-CoV-2 response across diverse Immunoglobulin (Ig) classes and SARS-CoV-2 antigens are needed 64 observed a genuinely good correlation across the diverse spike parameters tested (Fig. 2d) . The 214 notable exception were classical EC50 values, which showed no to weak correlation across all 215 parameters including the commercial test. Interestingly, AUC values, which in contrast to EC50 are a 216 composite measure of concentration and signal strength, performed well. Of note, we observed highly 217 variable SARS-CoV-2 antibody dose response curves, reaching in our cohort individual plateaus over a 218 4-log range ( Supplementary Fig. 7) . These plateaus are respected in the AUC readout, and are also 219 recorded by the basic MFI-FOE ABCORA readout at 1/100 plasma dilution, but are not considered in 220 EC50 determinations. Indeed the basic MFI-FOE showed a high correlation with the quantitative 221 readouts across the tested variables including the quantitative commercial Roche Elecsys S test. 222

Based on these results, we concluded that the MFI-FOE readout at 1/100 provides an excellent 223 estimate for the S1 and RBD antibody content in plasma and that this straightforward and easily 224 obtainable readout, which only requires a single plasma dilution to be tested, can be used as a proxy 225 for quantification. We therefore employed the basic MFI-FOE in a next step to define neutralization 226 predictors. in line with previous findings 5, 8 . Early in infection (within 30 days of positive RT-PCR) neutralization 231 titers were significantly higher (p<0.001) and correlated better with binding parameters. As expected, 232

IgG responses to spike antigens showed the highest correlation with neutralization activity (Fig. 3b, . We next grouped patients based on the population into high (NT50 >250, 234 N=135) and no or low neutralizers (NT50 <250, N=332) 38 (Fig. 4a ) and compared the prediction ability 235 of six different classification models to assign individuals based on their ABCORA 2.0 binding patterns 236 to these groups. Univariable logistic regression (ULR) models included only one variable: either the 237 mean of MFI-FOE S1 reactivities (ULR-S1), or the mean of MFI-FOE RBD reactivities (ULR-RBD). A 238 multivariable logistic regression (MLR) included both S1 and RBD mean reactivities. The additional 239 models included all 12 antigen reactivities measured in ABCORA and comprised a random forest 240 approach and two MLR strategies based on principle component analysis (PCA, 2 and 4 first axis). 241

Models were compared based on AUC and the BIC (Bayesian information criterion 39 ) by cross 242 validation (Fig. 4b, c) . All models performed similarly, with the univariable model based on the mean 243 of S1 reactivities (ULR-S1) yielding the best BIC value. Receiver operating curve (ROC) analysis based 244 on ULR-S1 showed a good capacity in predicting neutralization status yielding AUC 0.90 (N= 467, Fig. 245 4d) . Exploring different cutoffs to balance sensitivity and specificity keeping both above 80%, we chose 246 to assign samples to the high neutralizers group if its predicted probability was above 70%. This 247 corresponds to an 83% specificity in correctly assigning non-neutralizers and 80% sensitivity in 248 assigning neutralizers (Fig. 4d, e) . To increase the utility of the ULR-S1 prediction model for clinical 249 diagnostics, we devised a modified neutralization prediction model ULR-S1-SOC based on the SOC 250 values reported for ABCORA 2.0. At 70% predicted probability, ULR-S1-SOC delivers neutralization 251 prediction at similar sensitivity (81%) and specificity (81%) by examining if the composite S1 SOC value 252 (sum of S1 SOC values for IgG, IgA and IgM) is below or above 9.7 (Fig. 4f) . Thus, based on ULR-S1-SOC 253 neutralization activity can be ranked directly from the basic SOC readout. We therefore conclude that 254 the basic readout in ABCORA 2.0 can deliver a reliable prediction of high neutralization activity. 255 256

Cross-sectional analysis of antibody reactivity post SARS-CoV-2 diagnosis by RT-PCR (N=369) and post 258 onset of symptoms (N=333) underlined the capacity of ABCORA seroprofiling to dissect onset, peak 259 and waning of SARS-CoV-2 antibody responses ( Fig. 5a, b, Supplementary Fig. 10 ). In individuals with 260 known date of first SARS-CoV-2 RT-PCR diagnosis or onset of symptoms, ABCORA 2.3 detected early 261 seroconversion in 98% (48 of 49) and 100% (9 of 9) of individuals within 7 days post RT-PCR and onset 262 of symptoms, respectively. Besides IgM and IgA reactivity, IgG responses were readily detectable in 263 ABCORA 2.0 after a few days of infection ( Supplementary Fig. 10) . 264

Longitudinal assessment of a cohort of convalescent patients up to 11 months post infection (251 265 measurements on 120 patients) highlighted the temporal dynamics of SARS-CoV-2 binding antibodies. 266

We estimated the decay of binding reactivity employing a linear mixed model and identified a 267 significant reduction in RBD, S1, and N in all Ig subtypes ( Fig. 5b) with half-lives ranging from 116 to 268 836 days, with IgG N titers decaying the fastest, in line with previous reports 10 . Half-lives of the 269 neutralization relevant IgG responses to RBD and S1 where 209 and 323 days, respectively. Intriguingly, 270 the kinetics of neutralizing antibodies did not mirror the decay rates observed for binding antibodies. 271

Neutralization activity decreased overall at a slower rate, with a half-life of 410 days (Fig 5c) . This was 272 in part due to a mixed reactivity pattern with some individuals showing an increase in neutralization 273 activity post positive SARS-CoV-2 RT-PCR 5 , while neutralization activity in others rapidly decayed 274 ( Supplementary Fig. 10c) . 275 276

To enable a more detailed analysis of HCoV antibody reactivity alongside SARS-CoV-2, we expanded 278 the bead antigen array to include S1 proteins of all four circulating HCoVs 279 HCoV-HKU1, HCoV-OC43) ( Supplementary Fig. 11a ). According to its capacity to monitor antibodies to 280 five coronaviruses we termed the assay ABCORA 5.0 and trained and validated it on the same cohorts 281 as ABCORA 2.0 ( Fig. 1) . To allow direct comparison with ABCORA 2.0 and use of the neutralization 282 prediction models, we used the threshold-/SOC-based analysis settings of ABCORA 2.0 also for ABCORA 283 5.0. Based on ABCORA 5.0 measurements of training cohorts I-III, we devised two random forest-based 284 analysis models. ABCORA 5.4 included solely the 12 SARS-CoV-2 parameters, ABCORA 5.5 included in 285 addition the S1 HCoV measurements adding up to 24 parameters in total. In analogy to ABCORA 2.3, 286 incorporation of HCoV reactivity into the model was advantageous. ABCORA 5.5 provided the highest 287 sensitivity and specificity amongst the analysis algorithms probed ABCORA 5.0 ( Supplementary Fig.  288 11b, Supplementary Table 10) . 289

Interdependencies between antibody reactivity to the four HCoVs and SARS-CoV-2 mirrored what we 290 previously observed for HKU1 with a particular high correlation of IgM reactivity of SARS-CoV-2 and 291

HCoVs in pre-pandemic individuals, particularly in those with recent HCoV infection (Supplementary 292 Fig. 12 ). HCoV infections are frequent but subject to seasonality and prevalence of individual HCoV 293 infections fluctuates 40, 41 . In line with this, the prevalence of HCoV responses measured by ABCORA 5.0 294 in local blood donors in January 2019 (N=285), May 2019 (N=288), and January 2020 (N=252) varied 295 considerably (Fig. 6 ). To enable a time-controlled comparison of HCoV reactivity between SARS-CoV-296 2-infected and healthy donors, we screened blood donors from May 2020 (N=672), when SARS-CoV-2 297 prevalence was estimated below 2% in Zurich, Switzerland 42 , by ABCORA 2.0/5.0 and excluded all 298 samples with SARS-CoV-2 reactivity. The residual May 2020 cohort (N= 653) formed a pandemic, 299 healthy donor control group. Interestingly, HCoV reactivity patterns in 2019 and 2020 differed 300 substantially as assessed by one-way ANOVA, with January 2020 showing the comparatively lowest 301 and May 2020 the highest IgA and IgG reactivity, which may indicate a later onset of an HCoV epidemic 302 in 2020 compared to 2019 (t-tests of May 2020 versus other groups shown in Fig. 6 ). 303

Most intriguingly, a time-matched analysis comparing May 2020 healthy donors with SARS-CoV-2-304 positive patients sampled in April, May and June 2020 (N=65) revealed significantly lower HCoV 305 reactivity in SARS-CoV-2 positive patients (Fig. 7a ). This pattern was also evident when we extended 306 the analysis to include the full cohort of SARS-CoV-2 infected individuals measured with ABCORA 5.0 307 (N=389, sampled from March 2020 to February 2021, Supplementary Fig. 13 ). Overall, this raised the 308 possibility that pre-existing immune responses to HCoVs may to a certain degree protect against SARS-309

CoV-2 infection. We therefore investigated whether HCoV responses are linked to the evolution of 310 SARS-CoV-2 antibodies in patients with known date of first positive RT-PCR (SARS-CoV-2 patients 311 measured in ABCORA 5.0 with time since positive RT-PCR<60 days, N=204). Associations were 312 investigated with a linear regression model adjusted for age, gender, time since positive RT-PCR and 313

HCoV reactivity. To stratify HCoV reactivity into high and low HCoV activity, median logMFI-FOE were 314 defined for each HCoV and antibody class. LogMFI-FOE higher than the corresponding median for at 315 least three HCoVs (HKU1, OC43, NL63 or 229E) in a specific Ig class were ranked as having high HCoV 316 activity within this class. First, only reactivities among the same antibody class were explored in the 317 model (i.e. HCoV IgG high on SARS-CoV-2 IgGs). We observed exceptionally strong interdependencies 318 for IgA and IgM responses to SARS-CoV-2, which all were significantly higher in individuals with high 319

HCoV reactivity (Fig. 7b) . This strongly suggests that pre-existing HCoV immunity may provide an 320 advantage in mounting SARS-CoV-2 responses. Interdependencies between HCoV IgG and SARS-CoV-321 2 specific IgG were only observed for the S2 response. To explore if SARS-CoV-2 IgG may build on recent 322

HCoV IgA and IgM responses we next probed whether HCoV IgM and IgA are linked to elevated SARS-323

CoV-2 specific IgG levels. While no effect was evident for IgM, we observed a significant association of 324 high HCoV IgA activity on all four measured SARS-CoV-2 responses (Fig. 7c, d) . This strongly suggests 325 that recent HCoV infection has a beneficial effect on mounting SARS-CoV-2 antibody responses. 326 327 Discussion 328

Definition of SARS-CoV-2 immunity post vaccination and infection is of immediate importance 43-45 . 329 Deciphering antibody correlates of SARS-CoV-2 protection and monitoring vaccine responsiveness are 330 challenging tasks ahead. The magnitude and longevity of protective antibody responses to natural 331 infection and of different vaccines need to be examined to understand parameters that shape 332 protective responses and guide decisions on re-vaccination in non-responders and immunization 333 against novel arising SARS-CoV-2 variants 46 . Likewise, creating means to serologically distinguish 334 between de novo infection, re-infection, and vaccine responses, their durability and failures will be 335 critical for clinical diagnosis. 336

Here we demonstrate the high utility of multi-parameter seroprofiling in addressing key issues in 337 defining SARS-CoV-2 immunity. We designed SARS-CoV-2 seroprofiling tests, termed ABCORA, to 338 address research and clinical diagnostics needs. Simultaneous recording of antibody responses to a 339 range of SARS-CoV-2 antigens and different Ig classes with ABCORA seroprofiling yields an extensive 340 picture on the SARS-CoV-2 serology status in a single assessment. High accuracy in defining SARS-CoV-341 2 seropositivity and staging of seroconversion was achieved by a computational analysis. Validation 342 and verification of the performance of ABCORA against internal and external standards proved its 343 exceptional performance enabling application in clinical diagnostics and research. 344

Measuring neutralization will remain the ultimate goal to determine protective immunity to infection 345 and immunization. Protective activity against novel arising SARS-CoV-2 variants needs to be 346 determined 46-51 . Collecting information on neutralizing activity in large population groups is however 347 challenging as cell-based neutralization assays are not in wide diagnostic use and have limited turnover 348 and scalability. Means to derive estimates of neutralization activity based on comparatively simpler 349 binding assays would therefore provide an enormous advantage as previously suggested 52-54 . As we 350 demonstrate, computational modeling allows predicting plasma neutralization capacity from ABCORA 351 seroprofiling results, obliterating the need to conduct labor-intensive and costly neutralization tests in 352 clinical diagnostics or in large-scale research-based screens. The same principle can be applied in future 353 assay extensions to predict neutralization activity against novel SARS-CoV-2 variants. 354

The successful development of a sensitive seroprofiling test enabled a precise analysis of SARS-CoV-2 355 antibody dynamics and their interplay with HCoV responses. We utilized two ABCORA assay versions 356 that both measured HCoV reactivity alongside the 12 SARS-CoV-2 parameters. ABCORA 2 included the 357 S1 antigen of HKU1. ABCORA 5 included S1 of all four circulating HCoVs. Notably, computational 358 models that included the HCoV measurements allowed a higher precision in determining SARS-CoV-2 359 seropositivity, highlighting interdependencies between HCoV and SARS-CoV-2 responses that need to 360 be resolved. Recording reactivity against all four HCoVs in SARS-CoV-2 uninfected and infected 361 individuals we observed intriguing associations. Uninfected individuals displayed higher HCoV 362 reactivity compared to infected individuals. However, amongst persons with documented SARS-CoV-2 363 infection, those with high HCoV reactivity developed higher SARS-CoV-2 antibody levels. While 364 association studies as ours cannot formally define causality, the implications of our findings are 365 evident: Prior immunity to HCoV may protect to some extent against SARS-CoV-2 acquisition and may 366 provide a boost to the development of SARS-CoV-2 specific immunity. While we solely measured 367 antibody responses, a potential protective effect of HCoV immunity against SARS-CoV-2 acquisition 368 should not be viewed restricted to antibody activity. Antibodies and cellular immunity may both be 369 relevant and act in concert [55] [56] [57] . Alternatively, antibody responses measured in the present study may 370 solely document recent HCoV infection and deliver a surrogate measurement of other protective HCoV 371 responses. The link between higher HCoV and SARS-CoV-2 reactivity in infected individuals is 372 particularly intriguing. Strongest effects were seen for IgM and IgA HCoV responses, suggesting that 373 recent HCoV immunity provides an early boost to SARS-CoV-2 antibody development. Whether this is 374 due to cross-reactive B cell responses on which the SARS-CoV-2 immunity builds on and matures or 375 whether cross-reactive T helper activities play a role will be important to resolve in forth-coming 376 studies. Likewise the precise role and timing of the HCoV responses that shape SARS-CoV-2 antibody 377 responses needs to be defined. Early, low affinity HCoV responses may have a positive impact for the 378 evolution of SARS-CoV-2 immunity by providing an immune memory to build on, while the boosting of 379 non-protective cross-reactive HCoV antibodies may have a negative impact following the antigenic sin 380 principle 30 . 381 382 Our findings have multiple implications and warrant further investigation of the interplay between 383

HCoV and SARS-CoV-2 immunity. A modest protective effect by HCoV immunity would be a plausible 384 explanation for the high proportion of asymptomatic and mild SARS-CoV-2 infections 58,59 . Even more 385 intriguing are future perspectives. As others and we have shown, SARS-CoV-2 and HCoV immunity to 386 infection is often not long-lasting (Fig. 5, Supplementary Fig. 10 ) 5,60 , a limitation that SARS-CoV-2 387 antibody titers. Cross-sectional analysis was based on samples with known time since positive RT-PCR 417 (N=369) or known time since symptom onset (N=333), both including the longitudinal analysis 418 observations. Both, time since positive RT-PCR and time since onset were known for 330 samples, with 419 a median time of 3 days between symptom onset and RT-PCR (1 st -3 rd quartile: 1-7 days). Longitudinal 420 analysis of antibody reactivity was based on 251 observations from 120 convalescent patient with antibody reactivity due to immune compromising or elevated HCoV antibody reactivity due to recent 430 or recurring HCoV infection may occur. As this group is diagnostically relevant we considered it prudent 431 to include this cohort as Training II data set to verify if cross-reactivity with SARS-CoV-2 in ABCORA 432 occurs in this setting. Training II data were not included in the threshold definition to not over-433 represent individuals with severe illness. This HCoV infected group displayed overall lower reactivity 434 with SARS-CoV-2 than plasma from healthy adults but importantly showed no indication of cross-435 reactivity ( Fig. 1a, b) . Pandemic samples from anonymous blood donors with unknown SARS-CoV-2 436 status collected in May 2020 (N=672) were not included in training and validation cohorts. 437 438

His-tagged SARS-CoV-2-derived antigens (receptor binding domain (RBD), subunit S1 (S1), subunit S2 440 (S2), nucleocapsid protein (N)) and S1 of the four circulating HCoVs (HKU1, OC43, NL63, 229E) were 441 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We established two bead-based multiplexed SARS-CoV-2 immunoassays (ABCORA 2.0 and ABCORA 449 5.0) that included a range of SARS-CoV-2 and HCoV antigens (Sino Biological Europe GmbH, Eschborn, 450 Germany, Supplementary Table 12 ). Four SARS-CoV-2 antigens -RBD, S1, S2 and N -were included in 451 both ABCORA 2.0 and ABCORA 5.0. ABCORA 2.0 included in addition S1 of HCoV-HKU1, ABCORA 5.0 452 included S1 of all circulating HCoVs (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43). In brief, 453

individual MagPlex beads (Luminex Corporation, Austin, TX) with unique fluorescent bead regions were 454 chosen for each antigen, beads were coupled and mixtures of antigen-coupled beads incubated with 455 patient plasma in a 96-well plate set-up. Median Fluorescent Intensity (MFI) of bead-bound plasma 456 antibodies were measured utilizing a FlexMap 3D reader (Luminex Corporation, Austin, TX). We 457 designed the assay to fulfil the following criteria: i) high specificity, sensitivity and reproducibility, ii) 458 flexible multiplex design that allows straightforward addition and/or alteration of antigens; iii) wide 459 dynamic range; iv) optional quantification of antibody responses; v) optional recording of antibody 460 responses to HCoVs and vi) use in routine diagnostics and research. 461

We chose a sterically orientation capture via anti-His antibodies to ensure a homogenous antigen 462 display. Therefore, carboxylated MagPlex beads (Luminex Corporation, Austin, TX) were coupled with 463 anti-His antibody (Sino Biological Europe GmbH, Eschborn, Germany, Supplementary Table 10) and 464 then coupled with His-tagged antigens using Bio-Plex Amine coupling (Bio-Rad Laboratories AG, 465

Cressier, Switzerland) according to the manufacturer's instructions and as described 62 . 466 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Serum/plasma titration is in general considered the most accurate strategy to retrieve quantitative 467 information on antibody reactivity. However, in diagnostic use tests ideally should deliver (semi)-468 quantitative information from a single serum dilution to permit a sufficient throughput. The finalized 469 assay conditions covered a 2-log MFI range across all probed antigen-Ig combinations (Supplementary 470 Fig. 2 ). Ratifying the validity of using a single plasma dilution, we confirmed that plasma from SARS-471

CoV-2 positive patients and pre-pandemic SARS-CoV-2 negative plasma samples show optimal dose 472 response curves over a wide plasma dilution range ( Supplementary Fig. 2d ). Importantly, a 1/100 473 dilution of plasma was in all cases close to the maximum signal, underlining that increasing plasma 474 concentration would not increase signal intensity but rather endanger decreasing signals due to 475 prozone effects ( Supplementary Fig. 2d ). 476

Maximal anti-His antibody loading was achieved at 5 µg antibody per million beads (Supplementary 477 Several control measures were installed to ascertain inter-and intra-assay performance. To ascertain 486 a low assay-to-assay variability, large batches of individual antigen-loaded beads were prepared and 487 frozen in aliquots until use at -20°C to circumvent decay of the antigen-coupled beads (Supplementary 488 Fig. 1 ). Individual coupled beads were mixed on the test day to yield the required antigen bead cocktail. 489

Cocktails contained 60 beads per bead region per µl. In addition to the SARS-CoV-2 and HCoV bead 490 regions, each cocktail included an empty bead region (no antigen coupled) to control for unspecific 491 binding. Quality control and validation procedures for the FlexMap 3D instrument were done on each 492 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. be tested in the assay. A 1/100 plasma dilution was thus defined as the basic dilution for screening 502 plasma in ABCORA 2.0 when a qualitative (i.e. presence or absence of SARS-CoV-2 specific antibodies) 503 or semi-quantitative (i.e. MFI signal intensity) readout is required. 504

All ABCORA measurements were derived from single measurements unless stated otherwise. To 505 measure SARS-CoV-2 specific antibodies in patient plasma, heat inactivated plasma (1 h at 56°C) was 506 diluted 1/100 in PBS-BSA 1% unless otherwise stated. 50 µl diluted plasma were incubated with 50 µl 507 of the ABCORA antigen bead cocktail for 30 minutes at room temperature in 96-well plates, washed 508 three times with PBS-BSA 1% and incubated in separate reactions with phycoerythrin (PE)-labeled 509 detector antibodies for IgG, IgA or IgM at a final concentration of 1/500 in PBS-BSA 1%. This dilution 510 was previously defined by titration of the detector antibodies to yield optimal MFI signals. After 45 511 minutes of incubation at room temperature, beads were washed three times with PBS-BSA 1% and 512 analyzed in 96-well plates on the FlexMap 3D reader (Luminex Corporation, Austin, TX). A minimum of 513 50 bead reads per antigen was acquired. 514

To control for genuine cross-reactive antibodies, each plasma sample was assessed with beads without 515 antigen (empty bead control) in combination which each detector antibody. For analysis, raw MFI 516 values were transformed to MFI-FOE to correct for background binding. We established mean empty 517 bead MFI-FOE for IgG, IgA and IgM of pre-pandemic healthy donors (N=1016) and set the mean MFI-518 FOE + 4x standard deviation as threshold for the empty bead control. In absolute levels, these 519 thresholds amounted to MFI-FOE 41.58 (IgG), 55.91 (IgA) and 269.47 (IgM). Measurements for which 520 the empty bead control recorded values above this threshold were considered invalid and repeated. 521

Each Luminex analysis 96-well plate was set up to contain the same set of control samples 522 ( Supplementary Fig. 1c ), namely 7 serial 4-fold dilutions of a SARS-CoV-2 positive control donor pool 523 (N=20 donors, starting dilution 1/100, Supplementary Fig. 2d ) and a pre-pandemic healthy donor pool 524 (dilution 1/100, N=20 donors, Supplementary Fig. 2d ). These positive and negative controls allow to 525 control assay performance across independent measurements and in addition enable retrospective 526 standardization against external controls if needed. Table 4 ). Threshold levels were set to reach an overall specificity above 99% and 532 included levels for border-line reactivity for IgG RBD, IgG S1 and IgG N to allow also modest antibody 533 reactivity to these antigens to be examined. MFI-FOE reads of individual samples were transformed 534 into signal-over cut-off (SOC) values (MFI-FOE/threshold). SOC values are used for assessing positive 535 reactivity for each individual antigen-antibody class combination, with SOC>1 denoting positive 536 reactivity, SOC<1 denoting negative reactivity. When setting individual thresholds, it must be 537 considered that for each of the 12 probed activities cross-reactivities may occur. With 12 individual 538 SOC parameters recorded, overall specificity will decrease if any positive SOC independently suffices 539 to rate a sample overall as SARS-CoV-2 antibody positive. To exemplify: Assuming independent 540 responses, even a high 99% specificity for each antigen will add up to an overall low 88% specificity 541 across the entire assay. We thus required for SARS-CoV-2 positive calling in ABCORA 2.0 a minimum of 542 two specificities to reach activity above threshold. The combined SOC values used to define the overall 543 serostatus of a given sample are detailed in Supplementary Table 5 . For IgG RBD, S1 and N, for which 544 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint we also recorded border-line SOC activity, we allowed for a combination of 1 antigen reactivity SOC>1, 545 the second reactivity SOC> border line. The final threshold and positive call criteria allowed for a 546 differentiation of partial (partial (early seroconversion with only IgM and IgA responses) to full 547 seroconversion (including IgG responses) (Supplementary Table 5 ). In addition, the criteria denote 548 samples with weak reactivity and/or indeterminate reactivity (Supplementary Table 5 ). 549

To ease comparison between ABCORA 2.0 and ABCORA 5.0 the same threshold cut-offs were used for 550 ABCORA 5.0. We chose not to create specific cut-off thresholds for HCoV antibody reactivity as an 551 accurate definition of a negative response is complex due to the wide-spread exposure to HCoVs and 552 considerable antibody cross-reactivity between them. HCoV responses were however included in the 553 statistical analyses as MFI-FOE values. 554 555

Classification of seropositive versus seronegative samples in ABCORA 2.1 was realized using logistic 557 regression. The identical training and validation data used for the establishment for ABCORA 2.0 were 558 used. As the ABCORA 2.0 binding reactivities were highly correlated, we included the following 559 variables in the model (Supplementary Fig. 6a ): the mean value of all IgG MFI-FOE responses (RBD, S1, 560 S2, N), the mean value of the IgA MFI-FOE responses against RBD, S1 and S2, and the mean value of 561 the IgM MFI FOE responses against RBD, S1 and S2. IgA and IgM responses to N were excluded as they 562

were not clustering with the other responses of the same Ig class ( Supplementary Fig. 6a ). The logistic 563 regression was used to estimate and predict the probability of a given sample to be positive (p) as 564 follows: 565 = exp ( 0+ * ( : , 1, 2, )+ * ( : , 1, 2)+ * ( : , 1, 2)) 1+exp ( 0+ * ( : , 1, 2, )+ * ( : , 1, 2)+ * ( : , 1, 2))

Parameters 0, , and were estimed on the training dataset. A sample was then defined as 567 positive if its predicted probability of being positive was above a threshold c'. This threshold was 568 defined as to obtain a specificity of at least 0.99 and maximal sensitivity on the training dataset 569 (similarly to c for the random forest). In summary, in ABCORA 2.1, any new sample is defined as 570 seropositive if its probability of being seropositive as estimated by the logistic regression is above c'. 571

Analyses were performed in R version 3.6.3. 572 573 Definition of SARS-CoV-2 seropositivity using random forest classification 574

Classification of seropositive versus seronegative samples in context of ABCORA 2.0 and ABCORA 5.0 575 was realized using a random forest approach following the basic setup of random forests as described 576 in 63 . The random forest itself was built of an ensemble of 1000 classification trees using MFI-FOE 577 responses (IgA, IgG and IgM against RBD, S1, S2, N). The probability of a sample being positive as 578 predicted by the random forest is the average of the probabilities over all 1000 trees. Finally, a sample 579 is defined as positive if its probability of being positive is above a threshold c, which is defined as to 580 obtain a specificity of at least 0.99 and a maximal sensitivity on the training dataset. In summary, any 581 new sample is defined as seropositive if its probability of being seropositive as estimated by the 582 random forest is above the threshold c. We conducted a series of random forest analyses that 583 considered either only SARS-CoV-2 responses or SARS-CoV-2 and HCoV responses in ABCORA 2.0 and 584 ABCORA 5.0: ABCORA 2.2 and ABCORA 2.3 were trained and used for prediction on ABCORA 2.0 data 585 and included only SARS-CoV-2 responses or SARS-CoV-2 and HKU1 responses, respectively. ABCORA 586 5.4 (SARS-CoV-2 responses only) and ABCORA 5.5 (SARS-CoV-2 and HCoV responses) were trained on 587 ABCORA 5.0 data. Details on the data inclusion for the respective models are listed in Supplementary 588 Table 3 and Supplementary Table 10 . Analyses were performed in R version 3.6.3 using packages 589 random Forest and ranger 64-67 . 590 591 592 593 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint

We used the Anti-SARS-CoV-2 Verification Panel for Serology Assays (NIBSC code: 20/B770, NIBSC) to 595 verify the performance of the ABCORA 2.0 and ABCORA 2.3 test. Serum samples of the verification 596 panel measured by ABCORA 2.0/2.3 as described and results compared with the results of 597 commercially available assays reported by the NIBSC ( 31 and Supplementary Table 6 ). We further 598 verified the sensitivity of the ABCORA 2 test in detecting SARS-CoV-2 infection in a direct comparison 599 with commercial tests. Antibody status of plasma from SARS-CoV-2 positive individuals (N=171) were 600 analyzed with the following test systems: Included test systems targeted the N protein (Elecsys® Anti-601 SARS-CoV-2 (Roche Diagnostics GmbH)), the RBD region of the S protein (Elecsys® Anti-SARS-CoV-2 S 602 assay (Roche Diagnostics GmbH)), and the S1 subunit (EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG)) 603

(Supplementary Table 7 ). All assays were performed according to the manufacturer's instructions in 604 the diagnostics unit of the Institute of Medical Virology, University of Zurich, Switzerland. 605

To define binding antibody titers, 8 serial 4-fold dilutions starting with a 1/25 dilution of plasma were 608 prepared and measured in ABCORA 2.0. To derive quantitative information, MFI values were corrected 609 for background activity (MFI-empty bead control) and we defined the area under the MFI curve (AUC) 610 across the dilution series for each antigen-Ig combination. As a second quantitative readout, we 611 calculated 50% effective titer concentrations (EC50) using a four-parameter logistic curve 612 (y=Bottom+(Top-Bottom)/(1+10^((logEC50-X)*HillSlope). 613 614 Quantification of SARS-CoV-2 S1 and RBD activity 615

We used two approaches to standardize SARS-CoV-2 S1 and RBD activity. The first was based on the 616 S1/RBD specific antibody CR3022 ( 37 and Supplementary Table 13 ). Serial dilutions of IgG, IgA and IgM 617 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint versions of CR3022 were used to create standard curves on RBD and S1 coated beads. The linear range 618 of the standard and sample dilution curve was used for quantitation. We fitted a four-parameter 619 logistic curve (y=Bottom+(Top-Bottom)/(1+10^((logEC50-X)*HillSlope) ( Supplementary Fig. 7b ) 620 through which MFI values of measured samples are interpolated into a corresponding concentration 621 of antibody (µg/ml). We used this approach to quantify the concentration of RBD and S1 antibody 622 reactivity in the positive donor control, and used titrations of the donor pool included on each ABCORA 623 plate to calculate the S1 and RBD content of plasma samples in relation to it. We used the same 624 strategy in combination with the WHO International Standard Anti-SARS-CoV-2 Immunoglobulin 625 (NIBSC 20/136 31 ) to defer IU/ml content of the internal ABCORA positive donor pool and the individual 626 specimen tested ( Supplementary Fig. 7) . The WHO International Standard consists of a pool of plasma 627 from individuals with confirmed SARS-CoV-2 infection. RBD and S1 content of the ABCORA positive 628 donor pool quantified via the polyclonal WHO standard was highly similar within each Ig class 629 ( Supplementary Fig. 7b ). In contrast, RBD values estimated by the mAb CR3022 were a factor 2.4 -3.9 630 lower than the corresponding S1 values, suggesting an affinity difference of CR3022 for the two 631 antigens ( Supplementary Fig. 7b) . slopes were calculated based on the respective estimated slopes. Analyses were performed in R 641 version 3.6.3 using packages lme4 68 and lmerTest 69 . 642 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

SARS-CoV-2 plasma neutralization activity was defined using an HIV-based pseudovirus system as 644 described 32 . The env-inactivated HIV-1 reporter construct pHIV-1NL4-3 ΔEnv-NanoLuc (pHIV-645 1Nanoluc) and HT1080/ACE2cl.14 cells were kindly provided by P. Bieniasz, Rockefeller University, NY, 646 USA. To create a SARS-CoV-2 spike expression plasmid (P_CoV2_Wuhan) and NanoLuc luciferase activity (relative light units, RLU) was measured after 5 min incubation at room 660 temperature on a Perkin Elmer EnVision reader. Input of SARS-CoV-2 pseudoviruses for neutralization 661 assays was adjusted to yield virus infectivity corresponding to 5-10 x10 6 RLU (corresponding to 100-662 250-fold over background RLU values) in the absence of inhibitors. To measure plasma neutralization 663 activity six serial 4-fold dilutions of plasma starting at a 1/25 dilution were prepared. 20 µl of the diluted 664 plasma and 20 µl of virus were pre-incubated for 1 h at 37°C and then 30 µl of the virus/plasma mix 665 were transferred to 384-well plates seeded with HT1080/ACE2cl.14 cells in a volume of 30 µl. This 666 resulted in a final concentration of the plasma starting dilution of 1/100. Plasma neutralization titers 667 causing 50%, 80% and 90% reduction in viral infectivity (NT50, NT80 and NT90, respectively) compared 668 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10. 1101 /2021 to controls without plasma were calculated by fitting a sigmoid dose-response curve (variable slope) 669 to the RLU data, using GraphPad Prism with constraints (bottom=0, top=100). If 50% inhibition was not 670 achieved at the lowest plasma dilution of 1/100, a 'less than' value was recorded. All measurements 671 were conducted in duplicates. 672 673

To compare the ability of SARS-CoV-2 binding activity measured in ABCORA 2.0 to predict the 675 neutralization status, we measured neutralization activity to Wuhan-Hu-1 in SARS-CoV-2 positive 676 individuals (N=467) and classified individuals as high neutralizers (NT50 >250, N=332) and low 677 neutralizers (NT50 <250, N=135). Six different classification models were designed to assign individuals 678 to the high or low neutralizers category, based on their ABCORA2.0 binding patterns we established 679 two univariable logistic regression (ULR) models that included mean MFI-FOE spike antigen S1 680 reactivities and mean MFI-FOE spike antigen RBD reactivities, respectively. S1 and RBD were chosen 681 due to their highest correlation with NT50 (r= 0.82 and r=0.80 for the total spike reactivities of S1 and 682 RBD respectively, Supplementary Fig. 9 ). In addition to these two ULR, we established a multivariate 683 logistic regression model including both mean S1 and RBD reactivities (MFI). We further devised three 684 models that considered all 12 SARS-CoV-2 binding parameters recorded by ABCORA 2.0. Two 685 multivariable logistic regression models were based on a principal component analysis on all binding 686 activities and included the first two (respectively four) principal components, which explained 60% 687 (respectively 75%) of the variance in the data. We also included in our model comparison a 688 classification based on a random forest analysis that incorporated all 12 SARS-CoV-2 binding activity 689

For all 6 models, performance was assessed in 100 cross-validation sets: each set was built by randomly 691 sampling without replacement among the 467 measurements available. 80% of the data set was used 692 to train the model (N=374). Prediction of neutralization status was realized on the other 20% (N=93) 693 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint and compared to the true NT50 value and neutralization status, using a roc curve. The area under the 694 curve (AUC) was computed for all 6 models in each cross-validation run. The Bayesian information 695 criterion (BIC) was computed for all 5 logistic regressions in each cross-validation run. 696

To increase the utility of the ULR-S1 prediction model for clinical diagnostics we devised a modified 697 neutralization prediction model ULR-S1-SOC based on the signal over cut-off (SOC) values reported for 698 ABCORA 2.0. The ULR-S1-SOC estimates the probability of NT50>250 based on the sum of S1 SOC 699 values for IgG, IgA and IgM as follows: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. Significance of Spearman rank correlations were assessed through asymptotic t approximation. 725

Differences in means between two groups with independent measures were tested using two-tailed t-726

tests. When applicable, multiple testing was adjusted using Bonferroni correction for multiple 727 comparisons. A one-way ANOVA with 3 degrees of freedom was used in addition to two-tailed t-tests 728 in Fig. 6 to provide insights on overall versus group comparison. When analyzing datasets including 729 repeated measurements of the same individuals (Fig. 3a, Fig. 5b, Fig. 5c, Supplementary Fig. 8a , 730 Supplementary Fig. 10b ), we used linear mixed models with time since positive RT-PCR or time since 731 symptom onset (continuous or binary variable) as fixed effect and individual as random effect. In the 732 case of Fig. 5c and Supplementary Fig. 10c , the decreasing slope of neutralization titers was estimated 733 by considering only individuals with neutralization titers above the detection levels (NT50>100) at their 734 first measurement. For all linear mixed models, a Wald test with two-sided hypothesis was used to 735 determine if the estimated slope was significantly different from 0. In addition, half-lives were 736 obtained from the decreasing slope estimated on the log of either MFI-FOEs (Fig. 5b, Supplementary  737 Fig. 10b) or NT50s (Fig. 5c, Supplementary Fig. 10c ) as follows: t1/2=log(2)/(slope*log (10)). In Fig. 7b  738 and 7c, linear regressions were used to estimate the association between hCoV and SARS-CoV-2 739 reactivities: a Student t-test with two-sided hypothesis was used to assess if this association was 740 significantly different from 0. 741

Serological measurements from all patients are made available in Supplementary Table 14 . 743 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Codes to assess serostatus based on the ABCORA 2.3 method are available at: 745 https://github.com/chlpasin/SARS-CoV-2-serology 746 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. as MFI) were calculated. (c) Titrated SARS-CoV-2 RBD and S1 responses were quantified using the RBD 951 specific monoclonal antibody CR3022 (produced as IgG, IgA and IgM; expressed as ng/ml) as external 952 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 standard. See Supplementary Fig.7 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 curve (AUC). Each dot corresponds to one cross-validation set. (c) Bayesian information criterion (BIC) 979 of the five models based on logistic regression. The different models are: Univariable logistic 980 regressions (ULR). ULR-RBD: mean of MFI-FOE RBD. ULR-S1: mean of MFI-FOE S1. Multivariable logistic 981 regression (MLR). MLR-S1, RBD: mean of S1 reactivity and mean of RBD reactivity. MLR-PCA2 and MLR-982 PCA4: MLR of 2 and 4 first axis of PCA analysis, respectively. PCA was based on all 12 SARS-CoV-2 983 antibody reactivities measured by ABCORA 2.0. Random forest (RF) including all antibody reactivities 984 measured by ABCORA 2.0. (d) ULR-S1 estimated ROC curve based on full data set (N=467). (e) 985

Measured NT50 value versus probability of NT50 >250 as predicted by ULR-S1 in five randomly chosen 986 validation sets (each symbol corresponds to a validation set). Purple colored symbols indicate a higher 987 than 0.70 probability of the respective sample to be neutralizing at NT50 >250 and are therefore 988 denoted as high neutralizers. Grey indicates samples with predicted neutralization NT50 <250, 989 therefore classified as no/low neutralizers. (f) Neutralization prediction based on a modified ULR-S1 990 model utilizing the diagnostic readout SOC instead of MFI-FOE values as input. Measured NT50 value 991 versus sum of S1 SOC values (IgG, IgA, IgM) are depicted. Dashed lines correspond to a NT50=250 992 horizontally and the sum S1 SOCs=9.7 vertically. The sum S1 SOCs=9.7 corresponds to the thresholds 993 depicted for ULR-S1 in (d) and (e). The grey shaded area corresponds to true positives (individuals with 994 NT50 >250 predicted as high neutralizers). 995 areas to the 95% confidence intervals. Antibody half-lives (t1/2 in days) from significant models are 1003 depicted. Significance was assessed using Wald tests on the slope parameters. (c) Linear mixed model, 1004

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 with time since RT-PCR as fixed effect and individual as random effect, estimating the decay of 1005 neutralizing capacity on 251 measurements from 120 individuals. Only individuals with NT50>100 at 1006 their first measurement were used to estimate the half-life. The purple line corresponds to the model 1007 estimation and the purple shaded area to the 95% confidence intervals. Significance was assessed 1008 using Wald tests on the slope parameters. 1009 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint ABCORA 5.0 HCoV logMFI-FOE values higher than the corresponding median in at least 3 HCoV 1031 measurements (HKU1, OC43, NL63 or 229E). Curves correspond to the models estimation and shaded 1032 areas to the 95% confidence intervals. p-values were obtained by running a Student t-test on the 1033 parameter associated to HCoV reactivity in the linear regression. (N) or SARS-CoV-2 spike protein subunit S1 (S1) with titered anti-N and anti-S1 mAbs and a SARS-CoV-1050 2 positive patient plasma pool. One of three independent experiments is depicted. (c) Median 1051 fluorescence intensity (MFI) at 1/100 dilution and the 50 % effective concentration (EC50) values for 1052 anti-N and anti-S1 mAbs, the SARS-CoV-2 positive patient pool (+PP), two individual SARS-CoV-2 1053 positive patient plasma (P1 and P2) and a plasma pool of pre-pandemic healthy donors (-PP). One of 1054 three independent experiments is depicted. (d) Final assessment of assay setup (5 µg anti-his Ab per 1055 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. Spearman correlation matrix of SARS-CoV-2 (RBD, S1, S2, N) and HKU1 S1 antigen reactivity (based on 1075 logMFI-FOE) in SARS-CoV-2 positive adults (N= 389), healthy, pre-pandemic adults (N=825), pre-1076 pandemic samples from patients recently infected with a circulating HCoV strain (N=75) and pre-1077 pandemic children (N=169). Non-significant correlations are left blank. Levels of significance are 1078 assessed by asymptotic t approximation of Spearman's rank correlation, and corrected by the 1079 Bonferroni method for multiple testing (p<0.05/420). 1080 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. with known date of symptoms onset (N= 333). Patients were stratified according to time since first 1102 diagnosis to investigate early (less than 30 days post symptoms onset, lavender) and late (more than 1103 30 days symptoms onset, turquoise) neutralization responses. Difference between these two groups 1104

was assessed with a linear mixed model with time since symptom onset (binary variable early/late) as 1105 fixed effect and individual as random effect and using a Wald test on the parameter associated with 1106 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 and orange shaded areas to the 95% confidence intervals. Antibody half-lives (t1/2 in days) from 1129 significant models are depicted. Significance was assessed using Wald tests on the slope parameters. 1130 (c) Linear mixed model estimating the decay of neutralizing capacity in patients separated by their 1131 neutralizing activity. Only individuals with NT50>100 at their first measurement were used to estimate 1132 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 specific responses for each antigen. Stars correspond to levels of significance of two-tailed t-tests 1156 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 comparing negative versus positive patients. Levels of significance are corrected by the Bonferroni 1157 method for multiple testing and indicated as follows: *p<0.05/12, **p<0.01/12, ***p< 0.001/12. 1158 1159 1160 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ng/ml RBD S1 RBD S1 Spike RBD S1 Spike RBD S1 Spike RBD S1 Spike Elecsys (U/ml) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint Patients were stratified according to time since first diagnosis to investigate early (less than 30 days post RT-PCR, lavender) and late (more than 30 days post RT-PCR, turquoise) neutralization responses. Difference between these two groups was assessed with a linear mixed model with time since RT-PCR (binary variable early/late) as fixed effect and individual as random effect and using a Wald test on the parameter associated with time since RT-PCR (***: p<0.001). (b) Linear regression analysis to define association between neutralization (reciprocal NT50) and antibody binding (MFI-FOE). Black lines indicate linear regression predictions and grey shaded areas correspond to the 95% confidence intervals. Results depict early (lavender), late (turquoise) and full cohort (black). n.s. denotes non-significant results. Levels of significance are assessed by asymptotic t approximation of Spearman's rank correlation, and corrected by the Bonferroni method for multiple testing (p<0.05/1200, see Supplementary Figures 8b and 9 ). Sum S1 SOCs mean of MFI-FOE RBD. ULR-S1: mean of MFI-FOE S1. Multivariable logistic regression (MLR). MLR-S1, RBD: mean of S1 reactivity and mean of RBD reactivity. MLR-PCA2 and MLR-PCA4: MLR of 2 and 4 first axis of PCA analysis, respectively. PCA was based on all 12 SARS-CoV-2 antibody reactivities measured by ABCORA 2.0. Random forest (RF) including all antibody reactivities measured by ABCORA 2.0. (d) ULR-S1 estimated ROC curve based on full data set (N=467). (e) Measured NT50 value versus probability of NT50>250 as predicted by ULR-S1 in five randomly chosen validation sets (each symbol corresponds to a validation set). Purple colored symbols indicate a higher than 0.70 probability of the respective sample to be neutralizing at NT50>250 and are therefore denoted as high neutralizers. Grey indicates samples with predicted neutralization NT50<250, therefore classified as no/low neutralizers. (f) Neutralization prediction based on a modified ULR-S1 model utilizing the diagnostic readout SOC instead of MFI-FOE values as input. Measured NT50 value versus sum of S1 SOC values (IgG, IgA, IgM) are depicted. Dashed lines correspond to a NT50=250 horizontally and the sum S1 SOCs=9.7 vertically. The sum S1 SOCs=9.7 corresponds to the thresholds depicted for ULR-S1 in (d) and (e).

The grey shaded area corresponds to true positives (individuals with NT50 >250 predicted as high neutralizers).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. Purple lines correspond to the models estimation and purple shaded areas to the 95% confidence intervals. Antibody half-lives (t1/2 in days) from significant models are depicted. Significance was assessed using Wald tests on the slope parameters.

(c) Linear mixed model, with time since RT-PCR as fixed effect and individual as random effect, estimating the decay of neutralizing capacity on 251 measurements from 120 individuals. Only individuals with NT50>100 at their first measurement were used to estimate the half-life. The purple line corresponds to the model estimation and the purple shaded area to the 95% confidence intervals. Significance was assessed using Wald tests on the slope parameters. t1/2: 410 d All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. ; https://doi.org/10.1101/2021.04.21.21255410 doi: medRxiv preprint May 2019 (N=288), January 2020 (N=252). Samples from May 2020 (N=672) were collected during the pandemic in Switzerland. Only samples without SARS-CoV-2 specific reactivity as defined by ABCORA were included (N=653). Stars correspond to levels of significance of two-tailed t-tests comparing the indicated groups. Levels of significance are corrected by the Bonferroni method for multiple testing and indicated as follows: *p<0.05/36, **p<0.01/36, ***p<0.001/36. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 21, 2021. 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 * ***

Days since positive RT-PCR Days since positive RT-PCR Days since positive RT-PCR

*** ** *** ***